单抗N-35相关肿瘤抗原血清学分布的实验研究

Experimental Study on the Serological Distribution of Tumor Associated Antigen Related with Monoclonal Antibody N-35

目的了解单抗N-35识别的肿瘤相关抗原在不同人群血清中分布的差异和意义.方法分别采用免疫印迹法和免疫沉淀法用单抗N-35对60例恶性肿瘤患者,30例良性病变者和30例健康体检者的血清进行肿瘤相关抗原的检测.结果免疫印迹法和免疫沉淀法检测的阳性率在下列组中分别为:早期恶性肿瘤63.33%、66.67%,中晚期恶性肿瘤均为56.67%,良性病变13.33%、16.67%,健康人0%;免疫印迹和免疫沉淀检测结果无明显差别;单抗N-35对应抗原在健康人、良性病变与肿瘤患者血清间的分布差异有显著性(P<0.01),在健康人和良性病变患者血清中的分布差异无显著性(P>0.05),在恶性肿瘤早期和中晚期患者血清中的分布差异无显著性(P>0.05).结论单抗N-35识别的肿瘤相关抗原主要存在恶性肿瘤患者的血清中,很少存在于良性病变患者血清中,不存在于健康人血清中.提示单抗N-35可作为筛查恶性肿瘤的候选抗体而进行临床应用开发.使用免疫印迹法可减少操作步骤,达到检测目的.

Objective To Monoclonal antibody （MAb） study the serological distribution of the tumor associated antigen related with N-35 in different groups of people. Methods Samples were taken from 60 patients with malignant tumor, 30 patients with benign diseases and 30 healthy persons. Serums then were western blotted and co-immunoprecipitated by MAb N-35 respectively. Results The positive rates by western blotting and co-immunoprecipitation were 63.33% , 66.67% in patients with early state malignant tumor, 56.67%, 56.67% in patients with medium and advanced malignant tumor, 13.33%, 16.67% in people with benign diseases and 0% for healthy persons, respectively. The positive rates had no distinct difference between western blotting and co-immunoprecipitation. However, there were significant difference among healthy persons, people with benign diseases and patients carried malignancy （P 〈 0.01 ）. It had no remarkable difference between healthy persons and people with benign diseases （P〉 0.05） and between patients with early state malignancy and patients with medium and advanced malignancy （P 〉 0.05）. Conclusions The tumor associated antigen related with MAb N-35 is mainly presented in the serum of patients with malignancy, hardly found in the serum of patients with benign diseases and has no presentation in the serum of healthy persons. The results indicates that MAb N-35 may be used as a marker for screening patients with malignancy. Western blotting is more easier for the test compared with co-immunoprecipitation.